Adaptimmune pledges $312M for Noile-Immune's T cell boosting tech in drive to deliver on TCR promise
When Adrian Rawcliffe officially steps into the CEO role at Adaptimmune in a few days, he will have a new partnership to execute in one of his first efforts to shore up some enthusiasm for its T cell therapy programs.
In a $312 million pact, the US-UK hybrid biotech has enlisted Noile-Immune for a next-generation project that will boost Adaptimmune’s SPEAR T cells with the Japanese company’s PRIME platform. In addition to the receptors engineered into the T cells, the resulting product would be armed with the cytokines IL-7 and CCL19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
